Abstract
Aptamer molecules represent an attractive approach in pharmacological therapy. Thrombin is a plasma serine protease that plays a key role in coagulation and haemostasis, also playing a relevant role in endothelial and smooth muscle cell functions. Thus, the development and use of direct thrombin inhibitors represents a potent tool in cardiovascular therapeutics. This review describes the status of direct thrombin inhibitors, focusing on aptamer-based drug candidates, that are at present in pre-clinical and in clinical trials. In addition, more recent research strategies in the design of novel aptamer thrombin inhibitors are presented and discussed. In particular, their structural, conformational, pharmacokinetic and pharmacodynamic properties are discussed in relation with the specificity of their binding to relevant thrombin exosites, which regulate the enzyme interaction with natural substrates and cellular receptors. Despite the addition of new effective anticoagulants to the therapeutic armoury, there remains a need for safer and effective anticoagulants. The aptamer- based thrombin inhibitors may represent an attractive approach for future developments of more potent and safer anticoagulants.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue
Volume: 7 Issue: 1
Author(s): Stefano Lancellotti and Raimondo De Cristofaro
Affiliation:
Abstract: Aptamer molecules represent an attractive approach in pharmacological therapy. Thrombin is a plasma serine protease that plays a key role in coagulation and haemostasis, also playing a relevant role in endothelial and smooth muscle cell functions. Thus, the development and use of direct thrombin inhibitors represents a potent tool in cardiovascular therapeutics. This review describes the status of direct thrombin inhibitors, focusing on aptamer-based drug candidates, that are at present in pre-clinical and in clinical trials. In addition, more recent research strategies in the design of novel aptamer thrombin inhibitors are presented and discussed. In particular, their structural, conformational, pharmacokinetic and pharmacodynamic properties are discussed in relation with the specificity of their binding to relevant thrombin exosites, which regulate the enzyme interaction with natural substrates and cellular receptors. Despite the addition of new effective anticoagulants to the therapeutic armoury, there remains a need for safer and effective anticoagulants. The aptamer- based thrombin inhibitors may represent an attractive approach for future developments of more potent and safer anticoagulants.
Export Options
About this article
Cite this article as:
Lancellotti Stefano and De Cristofaro Raimondo, Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue, Cardiovascular & Hematological Agents in Medicinal Chemistry 2009; 7 (1) . https://dx.doi.org/10.2174/187152509787047658
DOI https://dx.doi.org/10.2174/187152509787047658 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor
Current Clinical Pharmacology Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Prophylaxis of Venous Thromboembolism in Major Orthopedic Surgery: A Practical Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Flavonoids and Platelet-Derived Thrombotic Disorders
Current Medicinal Chemistry Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Metabolic Syndrome and Myocardial Infarction in Women
Current Pharmaceutical Design Diagnostic Performance of Magnetic Resonance Cholangiopancreatography (MRCP) for Biliopancreatic Cancer
Current Medical Imaging Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Biodegradable and Bioabsorbable Stents
Current Pharmaceutical Design Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Current Drug Safety Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Towards A Superior Streptokinase for Fibrinolytic Therapy of Vascular Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry